-
Remdesivir
API’s Name Indication Innovator Patent Expiry Date(The U.S) Remdesivir Antiviruls(Ebola, Covid-19) Gilead -
Pomalidomide
API’s Name Indication Innovator Patent Expiry Date(The U.S) Pomalidomide Oncology drug Celgene -
Nirmatrelvir
API’s Name Indication Innovator Patent Expiry Date(The U.S) Nirmatrelvir 3C-Like Protease (3CLPRO) Inhibitor And SARS-Cov-2 Mpro Inhibitor -
Eltrombopag
API’s Name Indication Innovator Patent Expiry Date(The U.S) Eltrombopag ITP & Aplastic anemia Novartis & GSK May. 20, 2023 -
Ruxolitinib
API’s Name Indication Innovator Patent Expiry Date(The U.S) Ruxolitinib Myelofibrosis Novartis Jul. 6, 2024 -
Crisaborole
API’s Name Indication Innovator Patent Expiry Date(The U.S) Crisaborole Atopic Dermatitis and Eczema Pfizer Jun. 11, 2026 -
Vericiguat
API’s Name Indication Innovator Patent Expiry Date(The U.S) Vericiguat Heart failure Bayer and MSD May. 24, 2031 -
Abrocitinib
API’s Name Indication Innovator Patent Expiry Date(The U.S) Abrocitinib Atopic Dermatitis Pfizer Feb.11, 2034 -
Rimegepant
API’s Name Indication Innovator Patent Expiry Date(The U.S) Rimegepant Migraine headache Biohaven Feb. 22, 2031 -
Elagolix 834153-87-6
API’s Name Indication Specification US DMF EU DMF CEP Elagolix CAS: 834153-87-6 Endometriosis In-House